SLDB
Solid Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.52
+3.82%Oct 26, 2026, 12:00 UTC
The European Commission granted orphan designation to Solid Biosciences' SGT-212 for the treatment of Friedreich's ataxia.
Source:Oct 20, 2026, 12:00 UTC
Solid Biosciences announced that seven abstracts were accepted for poster presentation at the ESGCT 2026 Annual Congress, scheduled for October 27–30 in Hamburg, Germany.
Source: